GlassScriptPhysician profile
Christina Glover
NPI 1356638845
$7,048.53
in general payments reported to CMS, 2019-2025
41 companies · $1,176 in 2025
The $1,176 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,177 · 2020: $413 · 2021: $257 · 2022: $730 · 2023: $923 · 2024: $1,373 · 2025: $1,176.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,471.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,471.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $941.77 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Novo Nordisk INC | $618.60 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $576.61 | 2019-2025 | Evenity, Prolia, Tepezza |
| Corcept Therapeutics | $558.09 | 2019-2025 | Korlym |
| Boehringer Ingelheim Pharmaceuticals, INC. | $529.43 | 2019-2025 | Jardiance |
| Abbott Laboratories | $421.43 | 2022-2025 | Freestyle Libre |
| Astrazeneca Pharmaceuticals LP | $404.76 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $278.59 | 2022-2024 | |
| Dexcom, INC. | $237.76 | 2023-2025 | Dexcom G6 Transmitter |
| Sanofi-Aventis U.S. LLC | $230.08 | 2019-2024 | |
| Abbvie INC. | $203.62 | 2019-2025 | Ubrelvy |
| Valeritas, INC. | $172.52 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $166.30 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $157.77 | 2019-2022 | |
| Cequr Corporation | $138.66 | 2024 | Cequr Simplicity |
Show all 41 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Beta Bionics, INC. | $129.26 | 2024-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
| Insulet Corporation | $128.55 | 2019-2025 | Omnipod |
| Pfizer INC. | $127.24 | 2019-2024 | |
| Radius Health, INC. | $121.02 | 2019-2025 | |
| Eisai INC. | $101.80 | 2020 | |
| Tandem Diabetes Care, INC. | $80.22 | 2019-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Ultragenyx Pharmaceutical INC. | $77.90 | 2019-2023 | |
| Amryt Pharma Holdings LTD | $75.30 | 2023 | Mycapssa |
| Medtronic, INC. | $73.67 | 2022-2025 | Intellis Adaptivestim, Minimed 780g |
| Merck Sharp & Dohme LLC | $71.16 | 2019-2022 | |
| Alexion Pharmaceuticals, INC. | $46.09 | 2024-2025 | Strensiq |
| Regeneron Healthcare Solutions, INC. | $45.62 | 2019 | |
| Kyowa Kirin, INC. | $39.51 | 2023-2024 | Crysvita |
| Sequel Med Tech, LLC | $36.45 | 2025 | Twiist |
| Averitas Pharma INC. | $29.49 | 2025 | Qutenza |
| Shire North American Group INC | $28.53 | 2019 | |
| Madrigal Pharmaceuticals | $25.18 | 2025 | Rezdiffra |
| Janssen Pharmaceuticals, INC | $21.93 | 2019 | |
| Ascensia Diabetes Care US INC. | $21.62 | 2025 | |
| Recordati_rare_diseases_inc. | $21.47 | 2023 | Signifor Lar, Isturisa |
| Chiesi USA, INC. | $21.12 | 2024 | Mycapssa |
| Rhythm Pharmaceuticals, INC. | $18.97 | 2025 | Imcivree |
| Esperion Therapeutics, INC. | $17.98 | 2024 | Nexletol |
| Ascendis Pharma Endocrinology INC | $17.61 | 2023 | |
| Xeris Pharmaceuticals, INC. | $17.54 | 2024 | Gvoke Hypopen |
| Ibsa Pharma INC. | $17.31 | 2024 | Tirosint, Licart |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christina Glover listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.